Dr. Reddy's Laboratories Ltd ADR(RDY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low12.93
Day High12.93
Open:12.93
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Dr. Reddy’s to Announce Q1 FY27 Results and Host Earnings Call on July 22, 2026
Tipranks
Dr. Reddy’s Files Form 6-K and Publishes July 9 Investor Call Recording
Tipranks
Dr. Reddy’s Delays Semaglutide Supply After API Quality Issue Identified
Tipranks
Dr. Reddy’s Sets July 22 Board Meet, Imposes Trading Blackout for Q1 FY27 Results
Tipranks
Dr. Reddy’s Announces 42nd AGM via Video Conference and Final Dividend Details
Tipranks
Dr. Reddy’s Allots 6,730 ESOP Shares, Expands Issued Capital
Tipranks
Analysts’ Top Healthcare Picks: Dr Reddy’s Laboratories (RDY), Amgen (AMGN)
Tipranks
Dr. Reddy’s launches first-to-market generic Bosutinib 400mg in U.S. oncology market
Tipranks
Dr. Reddy’s Schedules June 2026 Analyst and Investor Meetings in Mumbai and Hyderabad
Tipranks
Dr. Reddy’s Files Clean Secretarial Compliance Report for FY 2026
Newswire.ca
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
Tipranks
Dr. Reddy’s to Ring NYSE Closing Bell Marking 25 Years on Wall Street
SYNDTGAM
Generic Ozempic to hit pharmacies this week, but availability will vary across Canada
FILE PHOTO: Pens for the diabetes drug Ozempic sit on a production line to be packaged at the Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo
Tipranks
Dr. Reddy’s Files Form 6-K and Publishes FY26 Earnings Call Transcript
Tipranks
Dr. Reddy’s Schedules Global Investor Meetings for Late May–Early June 2026
Tipranks
Dr. Reddy’s Launches First Generic Semaglutide Injection in Canada After Health Canada Nod
MarketBeat
Dr. Reddy's Laboratories Q4 Earnings Call Highlights
MarketBeat.com
Tipranks
Dr. Reddy’s Earnings Call: Growth vs. Margin Pain
Tipranks
Dr. Reddy’s Files Q4 FY26 Audited Results Presentation with Exchanges

Profile

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.